Your browser doesn't support javascript.
loading
Activation of 2,4-Diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a Putative Dioxygenase.
Melief, Eduard; Bonnett, Shilah A; Zuniga, Edison S; Parish, Tanya.
Afiliação
  • Melief E; TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
  • Bonnett SA; TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
  • Zuniga ES; TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
  • Parish T; TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA tanya.parish@idri.org.
Article em En | MEDLINE | ID: mdl-30323042
ABSTRACT
The diaminoquinazoline series has good potency against Mycobacterium tuberculosis Resistant isolates have mutations in Rv3161c, a putative dioxygenase. We carried out metabolite analysis on a wild-type strain and an Rv3161c mutant strain after exposure to a diaminoquinazoline. The parental compound was found in intracellular extracts from the mutant but not the wild type. A metabolite consistent with a monohydroxylated form was identified in the wild type. These data support the hypothesis that Rv3161c metabolizes diaminoquinazolines in M. tuberculosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Quinazolinas / Fatores de Transcrição / Dioxigenases / Mycobacterium tuberculosis / Antituberculosos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Quinazolinas / Fatores de Transcrição / Dioxigenases / Mycobacterium tuberculosis / Antituberculosos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2019 Tipo de documento: Article